(6-氯-吡啶3-基)乙酸 | 39891-13-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (6-氯-吡啶3-基)乙酸
• 中文别名: 2-氯-5-吡啶乙酸；6-氯吡啶-3-乙酸；2-氯吡啶-5-乙酸；6-氯-3-吡啶乙酸；(6-氯-吡啶-3-基)乙酸
• 英文名称: 2-(6-chloropyridin-3-yl)acetic acid
• 英文别名: 6-chloro-3-pyridineacetic acid；(6-chloropyridin-3-yl)acetic acid；2-(6-chloro-3-pyridyl)acetic acid；2-chloropyridine-5-acetic acid；2-Chloro-5-pyridyl acetic acid
• CAS: 39891-13-9
• 化学式: C₇H₆ClNO₂
• mdl: MFCD01863172
• 分子量: 171.583
• InChiKey: XWVPSJPQWOVRHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  164-169°C
• 沸点：
  336.6±27.0 °C(Predicted)
• 密度：
  1.405±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  应存于室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2-(2-Chloropyridin-5-yl)acetic acid
Product Name:
Synonyms: 2-(6-Chloropyridin-3-yl)acetic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2-(2-Chloropyridin-5-yl)acetic acid
Ingredient name:
CAS number: 39891-13-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H6ClNO2
Molecular weight: 171.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

(6-氯-吡啶3-基)乙酸是一种含氮杂环类脂肪酸。这类化合物在药物合成研究中发挥着重要作用，例如布洛芬和吲哚乙酸等已经成功用作药物。

制备方法

(6-氯-吡啶3-基)乙酸的合成步骤如下：

1. 将8.72毫摩尔2-氯-5-氯甲基吡啶、催化剂（锌粉和氯化锂）以及溶剂DMF加入反应釜中。

2. 通入二氧化碳，使釜内压力达到3MPa，并将反应温度调节至40℃。维持此条件进行反应15小时。

3. 反应结束后，在反应釜中加入稀盐酸以酸化溶液，然后使用乙酸乙酯进行萃取。合并有机相后通过旋转蒸发去除液体，最后在真空条件下进一步干燥，从而得到(6-氯-吡啶3-基)乙酸。

具体来说，催化剂包括锌粉和氯化锂，其中氯甲基杂环化合物与锌粉、氯化锂的摩尔比为1:3:3。对于每毫摩尔2-氯-5-氯甲基吡啶，需要加入约2.8～2.9毫升DMF溶剂。

反应信息

• 作为反应物：
  描述：

  (6-氯-吡啶3-基)乙酸 在 硫酸 、 一水合肼 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 6.0h， 生成 2-(6-氯吡啶-3-基)乙酰肼
  参考文献：
  名称：

  Holla, B. Shivarama; Prasanna; Poojary, Boja, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 4, p. 864 - 868

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氯-5-吡啶乙腈 在 硫酸 作用下， 以 水 为溶剂， 反应 3.0h， 生成 (6-氯-吡啶3-基)乙酸
  参考文献：
  名称：

  Holla, B. Shivarama; Prasanna; Poojary, Boja, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2004, vol. 43, # 4, p. 864 - 868

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC AZA DERIVATIVES<br/>[FR] DÉRIVÉS AZA HÉTÉROCYCLIQUES SUBSTITUÉS
  申请人：GRUENENTHAL GMBH

  公开号：WO2013013817A1

  公开（公告）日：2013-01-31

  The invention relates to heterocyclic aza derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

  这项发明涉及杂环氮杂基衍生物作为辣椒素受体配体，含有这些化合物的药物组合物，以及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
• Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
  申请人：FRANK Robert

  公开号：US20130029962A1

  公开（公告）日：2013-01-31

  Substituted heteroaromatic pyrazole-containing carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds and also to a method of using these compounds for treating and/or inhibiting pain and further diseases and/or disorders.

  含有杂环吡唑基的羧酰胺和脲化合物作为辣椒素受体配体，含有这些化合物的药物组合物，以及使用这些化合物治疗和/或抑制疼痛以及进一步疾病和/或疾病的方法。
• [EN] IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE TYROSINES KINASES RÉCEPTRICES
  申请人：ASTEX THERAPEUTICS LTD

  公开号：WO2009150240A1

  公开（公告）日：2009-12-17

  The invention relates to new bicyclic heterocyclic derivative compounds, to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

  这项发明涉及新的双环杂环衍生物化合物，包括含有该化合物的药物组合物，以及利用该化合物治疗疾病，例如癌症。
• Benzodiazepine and Pyridodiazepine Derivatives
  申请人：Bunnelle William H.

  公开号：US20110288069A1

  公开（公告）日：2011-11-24

  The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , X 1 , Y 1 , Y 2 , and Y 3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating disease conditions using such compounds and compositions, and methods for identifying such compounds.

  本申请涉及式(I)的苯二氮卓和吡啶二氮卓衍生物，其中R1、R2、R3、R4、X1、Y1、Y2和Y3如规范中所定义。本申请还涉及包含这类化合物的组合物，以及使用这类化合物和组合物治疗疾病症状的方法，以及识别这类化合物的方法。
• [EN] TETRAHYDRO-BENZODIAZEPINONES<br/>[FR] TÉTRAHYDRO-BENZODIAZÉPINONES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015071393A1

  公开（公告）日：2015-05-21

  Disclosed are compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein W, X, Y, Z, R1, R2, R3, R4 and R5 are as described in this application, and methods of using said compounds in the treatment of cancer.

  本申请公开了具有I式化合物或其药用可接受盐的化合物，其中W、X、Y、Z、R1、R2、R3、R4和R5如本申请所述，并且使用所述化合物治疗癌症的方法。